Table 1. Patient Characteristics.
NA=not applicable. ICIs=Immune Checkpoint Inhibitors, BV=Brentuximab vedotin. IQR=interquartile range
| All patients | ICIs | No-ICIs | P value | |
|---|---|---|---|---|
| Patients: no(%) | 105 (100%) | 37 (35.2%) | 68 (64.7%) | NA |
| Median age at alloBMT (IQR in years) | 36 (25–49) | 32 (24–46) | 36 (25–51) | 0.2 |
| AlloBMT time period: (median) range in years | (2015) 2004–19 | (2018) 2015–19 | (2012) 2004–19 | <0.001 |
|
Sex: no. (%) Male |
55 (52%) | 18 (49%) | 37 (54%) | 0.6 |
| Female | 50(48%) | 19 (51%) | 31 (46%) | |
| Median prior treatments: no. (range) | 4 (1 – 9) | 3 (2–9) | 4 (1–7) | 0.9 |
| Prior autoBMT: no. (%) | 31 (29%) | 8 (22%) | 23 (34%) | 0.19 |
| BV: no. (%) | 46 (43.8%) | 26 (70.2%) | 20 (29.4%) | <0.001 |
| ICI as last therapy: no. (%) | 28 (27%) | 28 (76%) | 0 (0%) | NA |
| Median time from ICI to alloBMT: days (range) | NA | 51 (23–472) | NA | NA |
|
Ann Arbor stage at diagnosis: no. (%) Stage I-II |
47 (45%) | 13 (35%) | 34 (50%) | 0.1 |
| Stage III-IV | 58 (55%) | 24 (65%) | 34 (50%) | |
| Primary refractory disease | 23 (22%) | 9 (24.3%) | 14 (20.5%) | 0.7 |
| Relapsed disease | 82 (78%) | 28 (75.6%) | 54 (79.4%) | |
| Pre-alloBMT remission status: no. (%) Complete remission | 56 (53%) | 21 (57%) | 35 (51%) | 0.1 |
| Partial remission | 34 (32%) | 14 (38%) | 20 (29%) | |
| Stable disease | 15 (14%) | 2 (5%) | 13 (19%) |